Cargando…
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
Fibroblast growth factor receptor (FGFR) dysregulation is involved in a variety of tumorigenesis and development. Cholangiocarcinoma is closely related with FGFR aberrations, and pemigatinib is the first drug approved to target FGFR for the treatment of cholangiocarcinoma. Herein, we undertake bioch...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814635/ https://www.ncbi.nlm.nih.gov/pubmed/36698015 http://dx.doi.org/10.1038/s42004-022-00718-z |